YARW · Yarrow Bioscience, Inc. · Metrics
$20.00
+0.43 (+2.20%)
At close · Oct 29
Return incl. dividend (before tax)
Q3 2021 earnings call transcript
Market Cap
$52.15M
Shares
2.67M
Volume · Oct 29
228.61K
Avg daily vol (3M)
108.87K
YARW metrics
65 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$20.00
Market cap
$52.15M
Price action
20 metricsPrice change (1W)
+2.0%
Price change (30D)
-11.2%
Price change (3M)
-39.4%
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
84.9%
Annualized volatility (3M)
84.3%
Beta
—
RSI (14D)
42.2
Price vs SMA 50
-22.9%
Price vs SMA 200
—
Avg volume (3M)
108,866
Relative volume
2.1
Average dollar volume
$2.76M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
2.67M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
60.6×
reciprocal yield 1.6%
EV / EBITDA
—
EV / EBIT
—
P / sales
108.2×
reciprocal yield 0.9%
P / book
2.4
reciprocal yield 42.3%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-35.9%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
-26.9×
EV / revenue historical average (5Y)
-21.1×
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2025-11-06
Profitability
9 metricsGross margin
—
Operating margin
-4,134.6%
Trailing 12 months
Net margin
-3,881.5%
Gross profit (TTM)
−$2.42M
Operating profit (TTM)
−$19.93M
Net income (TTM)
−$18.71M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+40.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$482,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.4%
Year over year · more shares
Revenue CAGR (3Y)
+6.1%
Revenue CAGR (5Y)
-51.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-84.8%
Return on assets
-79.3%
Debt / equity
0.0
Current ratio
15.3
EBITDA (TTM)
−$19.91M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$22.93M
Latest balance sheet
Cash & equivalents
$22.93M
Total assets
$23.60M
Total debt
$0
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$16.93M
Capital expenditures (TTM)
$0
R&D (TTM)
$9.84M
SG&A (TTM)
$13.20M
Stock compensation (TTM)
$1.93M
R&D / revenue
2,041.1%
Stock compensation / revenue
399.6%
Ownership (13F)
9 metrics13F filers
47
13F filer change QoQ
+1
Institutional ownership
10.9%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
33.3%
Private-fund adviser ownership
28.2%
Active holders' share change QoQ
+2.6%
Holder tenure
3.4
Price vs estimated holder cost
+10.7%
Ownership (registered funds)
1 metricsIndex-fund ownership
0.4%
Short interest
3 metricsShort interest
4.9%
Latest settlement · 1.3 days to cover
Days to cover
1.3d
Short-squeeze score
43 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—